ethyl 6,7-dimethylimidazo<2,1-b>benzothiazole-2-carboxylate | 113508-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: ethyl 6,7-dimethylimidazo<2,1-b>benzothiazole-2-carboxylate
• 英文别名: Ethyl 6,7-dimethylimidazo[2,1-b][1,3]benzothiazole-2-carboxylate
• CAS: 113508-93-3
• 化学式: C₁₄H₁₄N₂O₂S
• 分子量: 274.343
• InChiKey: FCOFKKGEHRBJTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 6,7-dimethylimidazo<2,1-b>benzothiazole-2-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 10,11-dimethyl-7-thia-2,5-diazatricyclo[6.4.0.0^2,6]dodeca-1(8),3,5,9,11-pentaene-4-carboxylic acid
  参考文献：
  名称：

  Grandolini; Ambrogi; Perioli, Il Farmaco, 1993, vol. 48, # 1, p. 31 - 43

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-5,6-二甲基苯并噻唑 、 3-溴丙酮酸乙酯 以 乙二醇二甲醚 为溶剂， 以7%的产率得到ethyl 6,7-dimethylimidazo<2,1-b>benzothiazole-2-carboxylate
  参考文献：
  名称：

  [EN] IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS
  [FR] DÉRIVÉS IMIDAZO[2,1-B]THIAZOLE ET 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE UTILES EN TANT QU'INHIBITEURS DE S100

  摘要：

  化合物的化学式（I）或其药用盐。该化合物可用于治疗癌症、炎症性疾病、自身免疫性疾病或神经退行性疾病。

  公开号：

  WO2016042172A1

文献信息

• Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors
  申请人：Active Biotech AB

  公开号：US10385069B2

  公开（公告）日：2019-08-20

  A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.

  式 (I) 的化合物或其药学上可接受的盐。该化合物可用于治疗癌症、炎症性疾病、自身免疫性疾病或神经退行性疾病。
• Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles
  作者：Ian R. Ager、Alan C. Barnes、Geoffrey W. Danswan、Peter W. Hairsine、David P. Kay、Peter D. Kennewell、Saroop S. Matharu、Peter Miller、Peter Robson

  DOI：10.1021/jm00401a009

  日期：1988.6

  4H-Imidazo[2,1-c][1,4]benzoxazine-2-carboxylic acid (3) was found to possess potent activity in the IgE-induced rat passive cutaneous anaphylaxis model which may be predictive of clinical antiallergic activity. Compared to disodium cromoglycate (DSCG, 1), 3 was less active following iv administration but unlike DSCG showed very significant oral activity. To explore the structural requirements for this activity, a range of tricyclic compounds was prepared and their activities were measured. Individual 2-carboxylic acids derived from imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles showed iv activities up to 10(3) times as potent as DSCG and many of them showed significant oral activity. From these, imidazo[1,2-a]quinoxaline-2-carboxylic acid 114 has been chosen for further development.
• Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b]benzothiazoles
  作者：Giuseppe Trapani、Massimo Franco、Andrea Latrofa、Antonia Reho、Gaetano Liso

  DOI：10.1016/s0928-0987(01)00173-7

  日期：2001.10

  The imidazobenzothiazole compounds 3-17 together with the imidazobenzoxazole 18, and the imidazobenzoimidazole 19 were prepared and their cytotoxic activity evaluated at the National Cancer Institute (NCI) for testing against a panel of approximately 60 tumor cell lines. Compounds 5, 7, 8, and 16 exhibited interesting in vitro cytotoxic activity. The most active imidazobenzothiazole derivative 8 was further evaluated as a cytotoxic agent in the hollow fiber assay and showed a score greater than the minimum values for xenograft testing together with a net cell kill. Comparison with the results displayed in the in vivo assay by standard antitumor drugs in clinical use revealed a significant in vivo activity of the benzothiazole compound. COMPARE analyses for compounds 4-19 against the NCI's standard agent database show poor or no correlation, and it might suggest for these compounds a mechanism of action unrelated to that of any known drug. Furthermore. the benzothiazole 8 did not show significant antitumor activity in a panel of two xenotransplanted tumors (i.e. colon and non-small cell lung tumors). By computing the polar surface area of compounds 3-19 with the MAREA computer program it was established that the most active compounds 5, 7, 8, and 16 should experience good intestinal permeability. (C) 2001 Elsevier Science B.V. All rights reserved.
• AGER, IAN R.;BARNES, ALAN C.;DANSWAN, GEOFFREY W.;HAIRSINE, PETER W.;KAY,+, J. MED. CHEM., 31,(1988) N 6, 1098-1115
  作者：AGER, IAN R.、BARNES, ALAN C.、DANSWAN, GEOFFREY W.、HAIRSINE, PETER W.、KAY,+

  DOI：——

  日期：——
• IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS
  申请人：Active Biotech AB

  公开号：US20180282348A1

  公开（公告）日：2018-10-04

  A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.

表征谱图